Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bast

Showing results (291-300 of 560) with videos related to

Pageof 56
Sort By:
Carcinogenesis|July 11, 2006
Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cellsGong Yang, Daniel G Rosen, Imelda Mercado-Uribe, et al.
International Journal of Oncology|August 8, 2013
Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathwayZhenbo Zhang, Yaping Zhu, Yunli Lai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1988
High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancerW P Peters, E J Shpall, R B Jones, et al.
BMC Cancer|June 15, 2012
Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcomeJia Xu, Priya B Shetty, Weiwei Feng, et al.
Cell Cycle (Georgetown, Tex.)|July 25, 2006
Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathwayXiao-Feng Le, Isabelle Bedrosian, Weiqun Mao, et al.
Cancer Research|October 11, 1991
Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2L A Maier, F J Xu, S Hester, et al.
Progress in Clinical and Biological Research|January 1, 1992
Detection of minimal residual breast cancer in bone marrowC S Johnston, E J Shpall, S Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 1999
Lysophosphatidic acid induces urokinase secretion by ovarian cancer cellsT B Pustilnik, V Estrella, J R Wiener, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2007
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancerLyndsay Harris, Herbert Fritsche, Robert Mennel, et al.
American Journal of Obstetrics and Gynecology|January 31, 2012
Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disordersRichard G Moore, Michael Craig Miller, Margaret M Steinhoff, et al.
Pageof 56

Showing results (291-300 of 560) with videos related to

Sort By:
Pageof 56
Carcinogenesis|July 11, 2006
Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cellsGong Yang, Daniel G Rosen, Imelda Mercado-Uribe, et al.
International Journal of Oncology|August 8, 2013
Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathwayZhenbo Zhang, Yaping Zhu, Yunli Lai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1988
High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancerW P Peters, E J Shpall, R B Jones, et al.
BMC Cancer|June 15, 2012
Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcomeJia Xu, Priya B Shetty, Weiwei Feng, et al.
Cell Cycle (Georgetown, Tex.)|July 25, 2006
Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathwayXiao-Feng Le, Isabelle Bedrosian, Weiqun Mao, et al.
Cancer Research|October 11, 1991
Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2L A Maier, F J Xu, S Hester, et al.
Progress in Clinical and Biological Research|January 1, 1992
Detection of minimal residual breast cancer in bone marrowC S Johnston, E J Shpall, S Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 1999
Lysophosphatidic acid induces urokinase secretion by ovarian cancer cellsT B Pustilnik, V Estrella, J R Wiener, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2007
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancerLyndsay Harris, Herbert Fritsche, Robert Mennel, et al.
American Journal of Obstetrics and Gynecology|January 31, 2012
Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disordersRichard G Moore, Michael Craig Miller, Margaret M Steinhoff, et al.
Pageof 56